{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00942656: Not Applicable Interventional Completed Cardiovascular Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Vaccenic acid (VA) (t11 octadecenoic acid) is a positional and geometric isomer of oleic acid (c9-octadecenoic acid), and is the predominant trans monoene in ruminant fats (50%–80% of total trans content). Dietary VA can be desaturated to cis-9,trans-11 conjugated
linoleic acid (c9,t11-CLA) in ruminants, rodents,
and humans. Hydrogenated plant oils are another source of VA in
the diet, and it has been recently estimated that this source
may contribute to about 13%–17% of total VA intake. In contrast to suggestions from the epidemiological studies,
the majority of studies using cancer cell lines (Awad et
al. 1995; Miller et al. 2003) or rodent tumors (Banni et al.
2001; Corl et al. 2003; Ip et al. 1999; Sauer et al. 2004)
have demonstrated that VA reduces cell growth and (or) tumor
metabolism. Animal and in vitro studies suggest that
the anti-cancer properties of VA are due, in part, to the in
vivo conversion of VA to c9,t11-CLA. However, several additional
mechanisms for the anti-cancer effects of VA have
been proposed, including changes in phosphatidylinositol
hydrolysis, reduced proliferation, increased apoptosis, and inhibition
of fatty acid uptake. In conclusion,
although the epidemiological evidence of VA intake
and cancer risk suggests a positive relationship, this is not
supported by the few animal studies that have been performed. The majority of the studies suggest that any health benefit
of VA may be conferred by in vivo mammalian conversion
of VA to c9,t11-CLA. VA acts as a partial agonist to both peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ in vitro, with similar affinity compared to commonly known PPAR agonists. Hypolipidemic and
antihypertrophic bioactivity of VA is potentially mediated
via PPAR-/-dependent pathways.
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02241629: Phase 2 Interventional Completed Motion Sickness
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levophencynonate is the active enantiomer of phencynonate. Levophencynonate is an anticholinergic agent which can prevent acute motion sickness with an efficacy similar to scopolamine. It will take effect by competitive binding to central muscarinic acetylcholine receptors. In April 2017 levophencynonate was in preregistration phase for the vertigo treatment in China.
Class (Stereo):
CHEMICAL (RACEMIC)
Broxaterol is a β2 adrenoreceptor agonist used for the treatment of respiratory disease. Broxaterol produced a significant clinical improvement, an increase in FEV1 and a decrease in supplemental anti-asthmatic drugs used in patients with reversible airflow obstruction and in asthmatic children. The increases in FEV1 versus baseline were significantly maintained after the end of the treatment. Prompt disappearance of the asthmatic attack with significant improvement in lung function was observed in children. In two long-term controlled trials, the respiratory effects of broxaterol nebulizer solution were significantly greater than placebo. Moreover, broxaterol by metered dose inhaler was more effective than salbutamol after 3 months follow-up, showing the absence of tachyphylaxis. In long-term clinical evaluation, broxaterol has been shown to be well tolerated, with an incidence of adverse reactions equal to or less than that reported in the literature for other beta 2-agonists. The side effects most frequently associated with broxaterol were tremor, nervousness, and palpitations.
Status:
Investigational
Source:
NCT02666963: Phase 1 Interventional Completed Healthy
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02530255: Not Applicable Interventional Completed Alzheimer Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00880568: Phase 1 Interventional Completed Neoplasms
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
